Fortis-M, a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Oral Talactoferrin Alfa with Best Supportive Care in Patients with Advanced Non-Small Cell Lung Cancer Following Two or More Prior Regimens- by the Fortis-M Study Group

Annals of Oncology ◽

10.1016/s0923-7534(20)34343-x ◽

2012 ◽

Vol 23 ◽

pp. ixe23 ◽

Cited By ~ 1

Author(s):

S.S. Ramalingam ◽

J. Crawford ◽

A. Chang ◽

C. Manegold ◽

R. Perez-Soler ◽

...

Keyword(s):

Lung Cancer ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Best Supportive Care ◽

Small Cell ◽

Study Group ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

The Lancet ◽

10.1016/s0140-6736(09)61497-5 ◽

2009 ◽

Vol 374 (9699) ◽

pp. 1432-1440 ◽

Cited By ~ 796

Author(s):

Tudor Ciuleanu ◽

Thomas Brodowicz ◽

Christoph Zielinski ◽

Joo Hang Kim ◽

Maciej Krzakowski ◽

...

Keyword(s):

Lung Cancer ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Best Supportive Care ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind

Download Full-text

PD6-3-6: A phase 3 randomized, double blind, placebo-controlled study of patients with previously untreated extensive-stage small cell lung cancer (SCLC) treated with platinum plus etoposide chemotherapy with or without darbepoetin alfa

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283344.69129.a5 ◽

2007 ◽

Vol 2 (8) ◽

pp. S433-S434 ◽

Cited By ~ 2

Author(s):

Robert Pirker ◽

Rodryg Ramlau ◽

Wolfgang Schuette ◽

Petr Zatloukal ◽

Irene Ferreira ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Darbepoetin Alfa ◽

Small Cell ◽

Controlled Study ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Extensive Stage

Download Full-text

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)00099-1 ◽

2016 ◽

Vol 17 (6) ◽

pp. 822-835 ◽

Cited By ~ 192

Author(s):

Johan F Vansteenkiste ◽

Byoung Chul Cho ◽

Tonu Vanakesa ◽

Tommaso De Pas ◽

Marcin Zielinski ◽

...

Keyword(s):

Lung Cancer ◽

Adjuvant Therapy ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Cancer Immunotherapeutic

Download Full-text

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(12)70063-3 ◽

2012 ◽

Vol 13 (3) ◽

pp. 247-255 ◽

Cited By ~ 370

Author(s):

Luis Paz-Ares ◽

Filippo de Marinis ◽

Mircea Dediu ◽

Michael Thomas ◽

Jean-Louis Pujol ◽

...

Keyword(s):

Lung Cancer ◽

Randomised Controlled Trial ◽

Supportive Care ◽

Controlled Trial ◽

Best Supportive Care ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Randomised Controlled

Download Full-text

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30634-5 ◽

2019 ◽

Vol 20 (12) ◽

pp. 1655-1669 ◽

Cited By ~ 67

Author(s):

Kazuhiko Nakagawa ◽

Edward B Garon ◽

Takashi Seto ◽

Makoto Nishio ◽

Santiago Ponce Aix ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Egfr Mutated

Download Full-text

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(12)70412-6 ◽

2012 ◽

Vol 13 (11) ◽

pp. 1161-1170 ◽

Cited By ~ 108

Author(s):

Siow Ming Lee ◽

Iftekhar Khan ◽

Sunil Upadhyay ◽

Conrad Lewanski ◽

Stephen Falk ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer

BMC Cancer ◽

10.1186/1471-2407-10-85 ◽

2010 ◽

Vol 10 (1) ◽

Cited By ~ 23

Author(s):

Luis G Paz-Ares ◽

Sedat Altug ◽

Alexandra Thareau Vaury ◽

Jesús Corral Jaime ◽

Francesca Russo ◽

...

Keyword(s):

Lung Cancer ◽

Supportive Care ◽

Best Supportive Care ◽

Small Cell ◽

Phase Iii ◽

Controlled Study ◽

Induction Treatment ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(11)60545-x ◽

2011 ◽

Vol 377 (9780) ◽

pp. 1846-1854 ◽

Cited By ~ 251

Author(s):

Roy S Herbst ◽

Rafat Ansari ◽

Frederique Bustin ◽

Patrick Flynn ◽

Lowell Hart ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Line Chemotherapy

Download Full-text

PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non–Small Cell Lung Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2017.09.011 ◽

2017 ◽

Vol 99 (5) ◽

pp. 1314-1315

Author(s):

S.J. Antonia ◽

A. Villegas ◽

D. Daniel ◽

D. Vincente Baz ◽

S. Murakami ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Consolidation Therapy ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text